CytoDyn Inc. Financials

CYDY

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 17 available years

Income Statement	TTM	MAY 2026	MAY 2025	MAY 2024	MAY 2023	MAY 2022
Revenues
Revenue	$0	–	–	–	$0	$0
Cost of Revenue	$0	$31	-$17	$0	$21	$0
Gross Profit	$0	–	–	–	-$21	$0
General & Administrative	$44	$7	$7	$11	$17	$44
Research & Development	$27	–	–	$7	$3	$27
Total Operating Expenses	$146	$39	-$10	$18	$41	$146
Operating Income	-$145	-$39	$10	-$18	-$41	-$145
Non-Operating
Net Interest Expense	–	$0	$1	$0	–	–
Other Non-Operating Income (Expense)	–	-$4	-$6	-$32	–	–
EBT (Earnings Before Tax)	-$211	-$43	$4	-$50	-$80	-$211
Income Tax Expense	$0	$0	$0	$0	$0	$0
Net Income
Net Income	-$211	-$43	$4	-$50	-$80	-$211
Per Share Data
Revenue Per Share	$0.00	–	–	–	$0.00	$0.00
EPS (Basic)	-$0.31	-$0.03	$0.00	-$0.05	-$0.10	-$0.31
EPS (Diluted)	-$0.31	-$0.03	$0.00	-$0.05	-$0.10	-$0.31
Weighted Avg Shares (Basic)	676.9M	1.29B	1.21B	969.5M	836.5M	676.9M
Weighted Avg Shares (Diluted)	676.9M	1.29B	1.24B	969.5M	836.5M	676.9M
Shares Outstanding	676.9M	1.29B	1.24B	969.5M	836.5M	676.9M

CytoDyn (CYDY) financials: revenue, profit and margins

CytoDyn (CYDY) generated about n/a in revenue and -$57 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is CytoDyn profitable?+

CytoDyn reported about -$57 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

More on CYDY: Overview · Quality scorecard · DCF valuation · Dividend safety

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 30 Sept 2026, covering the period ending 31 Aug 2026, as reported to the SEC. Data last refreshed 15 Oct 2026. How this is calculated.

Fiscal year ends May.

Peers

Pharmaceutical Preparations · Pick stocks to compare with CYDY

CompareIntrinsic value

RGBPRegen Biopharma Inc.

$0.00+0.00%25

ABVCABVC BioPharma Inc.

$1.00-3.85%0

ALLRAllarity Therapeutics Inc.

$0.87-2.20%0

NXTSNexentis Technologies Inc.

$0.59-7.24%20

CRVOCervoMed Inc.

$1.60-8.57%10

LIXTLixte Biotechnology Holdings Inc.

$3.56+0.56%10

CLNNClene Inc.

$3.83-1.79%0

PVCTProvectus Biopharmaceuticals, Inc.

$0.05-4.00%16

Spot a number that looks wrong? Check it in CYDY's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CYDY

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.